[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cd276-affibody\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cd276-affibody":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100551043","early-phase-1-study-on-b7-h3-targeted-affibody-radioligand-probes-for-pet-imaging-of-solid-tumors-100551043",false,"NCT06454955","Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors","Study of B7-H3 Mediated Tumor Immune Response Using a Whole-Body Kinetic Approach in Whole-Body PET","Inclusion Criteria:\n\n1. Age range 18-75 years, open to both male and female participants;\n2. Participants must meet the following hematologic and hepatic\u002Frenal function criteria: Hematology: WBC ≥ 4.0 × 10\\^9\u002FL or neutrophils ≥ 1.5 × 10\\^9\u002FL, platelets ≥ 100 × 10\\^9\u002FL, hemoglobin ≥ 90 g\u002FL; Prothrombin time (PT) or Activated partial thromboplastin time (APTT) ≤ 1.5 times the upper limit of normal (ULN); Hepatic and renal functions: Total bilirubin (T-Bil) ≤ 1.5 times the upper threshold limit (ULT), ALT\u002FAST ≤ 2.5 ULN or ≤ 5 ULT for subjects with liver metastasis, Alkaline phosphatase (ALP) ≤ 2.5 ULN (or ≤ 4.5 ULN in cases of bone or liver metastasis); Blood urea nitrogen (BUN) ≤ 1.5 × ULT, serum creatinine (SCr) ≤ 1.5 × ULT;\n3. Normal cardiac function;\n4. Expected survival of at least 12 weeks;\n5. Good adherence to follow-up;\n6. Presence of at least one measurable target lesion according to RECIST 1.1 criteria;\n7. Women of childbearing age (15-49 years) must undergo a pregnancy test within seven days prior to the commencement of the study and test negative; sexually active male and female participants must agree to utilize effective contraception to prevent pregnancy during the study and for three months following the final examination;\n8. Patients for whom a clinical physician recommends PET\u002FCT scans for the diagnosis and staging of tumors;\n9. Participants must fully understand and voluntarily agree to participate in the study, and must sign an informed consent form.\n\nExclusion Criteria:\n\n1. Severe abnormalities in liver and renal function and blood counts;\n2. Patients planning to conceive;\n3. Pregnant or lactating women;\n4. Individuals unable to lie flat for thirty minutes;\n5. Individuals who refuse to participate in this clinical study;\n6. Individuals suffering from claustrophobia or other psychiatric disorders;\n7. Other situations deemed unsuitable for trial participation by the researchers.",true,"ALL","18 Years","75 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","Based on \\[68Ga\\]B7H3 Affibody-BCH, this study investigates its radioactive uptake and imaging capabilities in tumor patients, with the aim of establishing a correlation between radioactive uptake and B7-H3 receptor expression. Utilizing whole-body PET technology, the pharmacokinetic dynamics of \\[68Ga\\]B7H3 Affibody-BCH are examined to ascertain its pharmacological characteristics. Ultimately, this research establishes a framework for pharmacokinetic analysis using whole-body PET.",[28,29,30],"B7H3","CD276 Affibody","PET\u002FCT Imaing","RECRUITING","2024-08-21",{"date":34,"type":35},"2024-08-23","ACTUAL",{"date":37,"type":35},"2024-01-01",{"date":39,"type":22},"2026-11-30",{"name":41,"class":42},"Peking University Cancer Hospital & Institute","OTHER"]